Recce Pharmaceuticals Ltd (ASX:RCE) shares were down 5.8% during trading on Tuesday . The stock traded as low as A$0.25 ($0.17) and last traded at A$0.25 ($0.17), approximately 296,219 shares were traded during mid-day trading. The stock had previously closed at A$0.26 ($0.18).

The firm’s fifty day simple moving average is A$0.28 and its 200 day simple moving average is A$0.24. The company has a market capitalization of $32.79 million and a price-to-earnings ratio of -8.17. The company has a debt-to-equity ratio of 0.41, a current ratio of 0.36 and a quick ratio of 0.35.

About Recce Pharmaceuticals (ASX:RCE)

Recce Pharmaceuticals Ltd, a biotechnology company, researches and develops antibiotic drugs in Australia. The company focuses on the development of RECCE 327 that helps to address the problem of antibiotic resistant superbugs. It also develops drugs for the treatment of stomach ulcers and diarrhea. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017.

Featured Article: Is the QQQ ETF safe?

Receive News & Ratings for Recce Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recce Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.